These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 954353)

  • 1. Naltrexone: disposition, metabolism, and effects after acute and chronic dosing.
    Verebey K; Volavka J; Mulé SJ; Resnick RB
    Clin Pharmacol Ther; 1976 Sep; 20(3):315-28. PubMed ID: 954353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism and disposition of naltrexone in man after oral and intravenous administration.
    Wall ME; Brine DR; Perez-Reyes M
    Drug Metab Dispos; 1981; 9(4):369-75. PubMed ID: 6114837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics.
    Verebey K
    NIDA Res Monogr; 1981; 28():147-58. PubMed ID: 6791001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The urinary excretion profiles of naltrexone in man, monkey, rabbit, and rat.
    Dayton HE; Inturrisi CE
    Drug Metab Dispos; 1976; 4(5):474-8. PubMed ID: 10147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration.
    Meyer MC; Straughn AB; Lo MW; Schary WL; Whitney CC
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):15-9. PubMed ID: 6469932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The metabolism of naltrexone in man.
    Wall ME; Brine DR; Perez-Reyes M
    NIDA Res Monogr; 1981; 28():105-31. PubMed ID: 6790999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naltrexone disposition in man after subcutaneous administration.
    Wall ME; Perez-Reyes M; Brine DR; Cook CE
    Drug Metab Dispos; 1984; 12(6):677-82. PubMed ID: 6150815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimation of the systemic availability and other pharmacokinetic parameters of naltrexone in man after acute and chronic oral administration.
    Kogan MJ; Verebey K; Mule SJ
    Res Commun Chem Pathol Pharmacol; 1977 Sep; 18(1):29-34. PubMed ID: 905632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The seminal excretion, plasma elimination, tissue distribution and metabolism of naltrexone in the rabbit.
    Taylor SM; Rodgers RM; Lynn RK; Gerber N
    J Pharmacol Exp Ther; 1980 May; 213(2):289-99. PubMed ID: 7365688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative determination of naltrexone and beta-naltrexol in human plasma using electron detection.
    Verebey K; Kogan MJ; DePace A; Mulé SJ
    J Chromatogr; 1976 Apr; 118(3):331-5. PubMed ID: 1254668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of a naltrexone sustained-release preparation.
    Chiang CN; Hollister LE; Kishimoto A; Barnett G
    Clin Pharmacol Ther; 1984 Nov; 36(5):704-8. PubMed ID: 6488691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of liver cirrhosis on the systemic availability of naltrexone in humans.
    Bertolotti M; Ferrari A; Vitale G; Stefani M; Trenti T; Loria P; Carubbi F; Carulli N; Sternieri E
    J Hepatol; 1997 Sep; 27(3):505-11. PubMed ID: 9314128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naltrexone, 6 beta-naltrexol and 2-hydroxy-3-methoxy-6 beta-naltrexol plasma levels in schizophrenic patients after large oral doses of naltrexone.
    Verebey K; Mulé SJ
    NIDA Res Monogr; 1979; 27():296-301. PubMed ID: 121346
    [No Abstract]   [Full Text] [Related]  

  • 14. Testing of drug delivery systems for use in the treatment of narcotic addiction.
    Reuning RH; Malspeis L; Frank S; Notari RE
    Natl Inst Drug Abuse Res Monogr Ser; 1975; (4):43-5. PubMed ID: 827709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disposition and pharmacokinetics of naltrexone after intravenous and oral administration in rhesus monkeys.
    Reuning RH; Ashcraft SB; Wiley JN; Morrison BE
    Drug Metab Dispos; 1989; 17(6):583-9. PubMed ID: 2575491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A gas-liquid chromatographic method for the determination of naltrexone and beta-naltrexol in human urine.
    Verebely K; Mulé SJ; Jukofsky D
    J Chromatogr; 1975 Aug; 111(1):141-8. PubMed ID: 239958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elimination of radioactivity following administration of [15,16-3H]naltrexone to rats and guinea pigs.
    Ludden TM; Bathala MS; Malspeis L; Drum MA; Reuning RH
    Drug Metab Dispos; 1978; 6(3):321-8. PubMed ID: 26554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic reduction of naltrexone. I. Synthesis, separation and characterization of naloxone and naltrexone reduction products and qualitative assay of urine and bile following administration of naltrexone, alpha-naltrexol, or beta-naltrexol.
    Malspeis L; Bathala MS; Ludden TM; Bhat HB; Frank SG; Sokoloski TD; Morrison BE; Reuning RH
    Res Commun Chem Pathol Pharmacol; 1975 Sep; 12(1):43-65. PubMed ID: 810832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative determination of naltrexone, 6 beta-naltrexol and 2-hydroxy-3-methoxy-6 beta-naltrexol (HMN) in human plasma, red blood cells, saliva and urine by gas liquid chromatography.
    Verebey K
    NIDA Res Monogr; 1981; 28():36-51. PubMed ID: 6791012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum naltrexone and 6-beta-naltrexol levels from naltrexone implants can block very large amounts of heroin: a report of two cases.
    Brewer C
    Addict Biol; 2002 Jul; 7(3):321-3. PubMed ID: 12126492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.